Randomized Study to Determine Optimal Stopping Time of GLP-1 Receptor Agonists Before Colonoscopy to Improve Bowel Preparation Quality

What this Trial Is About

Researchers are evaluating how different stopping times of GLP-1 receptor agonists before a colonoscopy affect the quality of bowel preparation and the need for repeat procedures. These medications, used mainly for type 2 diabetes and weight management, slow stomach emptying and gut movement, which might reduce bowel cleansing effectiveness. The study aims to find the best discontinuation timing to improve colonoscopy results in patients using GLP-1 receptor agonists. Participants are randomly assigned to one of two groups stopping GLP-1 receptor agonists one week before colonoscopy or continuing these medications without stopping. Both groups undergo standard bowel cleansing with a polyethylene glycol regimen before the procedure. The study uses the Boston Bowel Preparation Scale BBPS to measure bowel cleanliness during colonoscopy and compares incomplete bowel preparation rates between groups. During the study, participants will have their bowel preparation quality assessed during colonoscopy and followed for 30 days afterward to monitor outcomes. Researchers will analyze the adequacy of bowel cleansing and the need for repeat colonoscopies. Participants must meet specific health criteria and are monitored for safety throughout the trial, which runs from June 2026 to June 2028.

Discontinuation Recommendations for GLP-1 Receptor Agonists Prior to Colonoscopy: A Randomized Controlled Trial in Taiwan.